Form 4: Rocket Pharmaceuticals Director Gotham Makker Reports Stock Option Grant

Director Gotham Makker reports the acquisition of stock options for Rocket Pharmaceuticals shares.

Summary

• Gotham Makker, a director of Rocket Pharmaceuticals, reported the acquisition of stock options.
• The transaction occurred on September 26, 2024.
• Makker acquired options to purchase 204 shares and 303 shares of Rocket Pharmaceuticals' common stock.
• The exercise price for both options is $17.60.
• The options become fully vested and exercisable on September 26, 2025.
• The options expire on September 26, 2034.
• Following the transaction, Makker directly owns options for 204 and 303 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director. While option grants can be seen as a positive incentive, this filing itself doesn't provide strong positive or negative signals.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates